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Abstract: 
Background: Adult African American (AA) asthmatics have high rates of nonadherence 
to pharmacotherapy; however little is known about interventions to improve adherence 
in this population.   
Purpose: To systematically review the literature on patient and family-level interventions 
aimed at improving pharmacotherapy adherence in adult AA asthmatics.    
Data Sources: MEDLINE®, EMBASE, Web of Science, and CINAHL from inception to 
February 2016; reference lists of key studies on this topic 
Study Selection: English-language studies enrolling adult AA asthmatics from the US 
comparing patient and/or family-level interventions to improve asthma pharmacotherapy 
with usual care, no intervention or another active intervention.  
Data Extraction: Two investigators independently selected, extracted data from and 
rated the risk of bias of relevant studies. 
Data Synthesis: 1,460 unique abstracts were identified from all sources, 3 randomized 
controlled trials (RCT) and 1 pre/post study met inclusion criteria. Studies ranged from 
17-333 participants who were predominately middle-aged (33-47 years), AA (71%-
93%), and women (69%-82%). The 3 RCTs enrolled patients with persistent asthma 
and evaluated three different types of interventions: problem solving, self-efficacy, and 
the use of patient advocates. All 3 compared the intervention with an active control 
featuring minimal asthma education, and we rated all three as having a medium risk of 
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bias. None of the RCTs found a statistically significant improvement in adherence, 
FEV1, asthma control, asthma self-efficacy, or health care utilization outcomes. The 
RCT assessing self-efficacy (N=42) found a clinical and statistically significant 
improvement in asthma quality of life (adjusted difference between groups: 1.8, 
p=0.002). The pre/post study (N=17) evaluated a pharmacist-led educational 
intervention enrolling hospitalized asthmatics; we rated this study as having a high risk 
of bias primarily due to selection bias. Compared with baseline, participants had 
improved adherence at 6 months (absolute increase adherence rate 41%, p=0.0175) 
and reduced asthma-related ED and hospital visits (absolute reduction 1.23 visits per 
person, p=0.0016).  
Limitations: Small, diverse body of literature with some methodological limitations such 
as attrition, selection bias and measurement bias; possible publication bias  
Conclusion: Few studies assessing asthma adherence interventions focused on adult 
AA populations. Limited data from one RCT suggests that interventions focused on self-
efficacy improve asthma related quality of life compared with controls. Although one 
pre/post study found improved adherence with a pharmacist-led intervention, none of 
the 3 included RCTs demonstrated improved adherence in participants randomized to 
an active intervention compared with controls.  
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Introduction 
Asthma is a chronic inflammatory disorder of the airways that is characterized by 
variable and recurring symptoms, airflow obstruction and bronchial hyper-
responsiveness.1,2 Evidence suggests that most patients with asthma can control their 
disease if they receive guideline-based care, use appropriate asthma pharmacotherapy, 
and modify their environment to reduce or eliminate exposure to allergens and 
irritants.2-7 However, adult African Americans are disproportionately burdened by 
asthma. African Americans are 20% more likely to have asthma compared with Non-
Hispanic whites (current asthma prevalence of 8.6% vs 7.3%); but, more than three 
times more likely to have a hospitalization (rate per 100,000 population, 297.9 vs 90.5) 
or death due to asthma (rate per 100,000 population, 2.6 vs 0.8) compared with Non-
Hispanic whites.8-10 While African American children with asthma have higher health 
care utilization rates, adult African American asthmatics have higher mortality rates.11   
Adherence to asthma pharmacotherapy is integral to preventing asthma 
exacerbations and can help reduce asthma disparities.12 Medication adherence is 
defined as the extent to which patients take medications as prescribed by their health 
care providers.13 Nonadherence to asthma therapy is associated with poor asthma 
health outcomes (e.g., asthma exacerbations, asthma quality of life, asthma control), 
increased health care utilization (e.g., emergency department visits, outpatient visits, 
hospitalizations) and asthma-related mortality.14,15 It is estimated that about 25% of 
asthma exacerbations in African Americans can be prevented by inhaled corticosteroid 
(ICS) adherence.12   
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Barriers to adherence occur at all levels of the socio-ecological framework and 
range from patient-related (e.g., cost, perceived effectiveness, and health beliefs), 
therapy-related (e.g., complexity of regimen, frequent medication changes, side effect) 
provider-related (e.g., patient-provider relationship, patient-provider communication), 
and health-system related (e.g., lack of continuity of care, poor access to appointments, 
patient information written at high literacy level).13,16 Patient characteristics associated 
with nonadherence include external variables such as minority race/ethnicity, low 
income, and non-private insurance and internal variables such as decreased readiness 
to take controller medication and unfavorable attitudes towards controllers.14,17-19  
Le et al., found that negative health beliefs mediated the relationship between 
minority race/ethnicity and poor adherence.20 When they controlled for negative health 
beliefs, the relationship between minority race/ethnicity was no longer significant 
(unstandardized, Beta = -0.25, p = 0.01 to Beta = -0.17, p=0.08).20 However Apter et al., 
did not achieve similar results when adjusting for attitude towards ICS.  Attitude was 
only associated with a 13% reduction in the race coefficient, which was lower than their 
a priori threshold limit of 15%. Their mediation analysis found that household income, 
commercial insurance, and symptoms within the prior 2 weeks was associated with a 
32%, 42% and 23% reduction in association between race/ethnicity and adherence, 
repsectively.14  
Prior systematic reviews exploring asthma adherence interventions have noted 
variable effectiveness in improving adherence and asthma clinical outcomes.21-25   A 
2003 systematic review of adult and pediatric asthmatics concluded that interventions 
with improved adherence and asthma control were often education interventions and 
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used subjective adherence and clinical outcome measures.21,25-28 In 2012 Moullec et al., 
reviewed adherence interventions in adult asthmatics and concluded that interventions 
with a higher number of chronic care model components (i.e., self-management, 
decision support, delivery system design, clinical information system) had higher ICS 
adherence--one component, standardized mean difference 0.29, 95% CI (0.16-0.42); 
two components 0.53 (0.40-0.66); four components 0.83, (0.69-0.98).23 A recent 
Cochrane Review of medication adherence interventions across all diseases concluded 
that there were few low risk of bias randomized controlled trials (RCT) that improved 
adherence and clinical outcomes.  They found no common intervention components in 
effective trials and small effect sizes overall.29  
Prior systematic reviews did not assess the effectiveness of adherence 
interventions in high-risk asthma populations (i.e., inner city, race/ethnic minorities, low 
income) who have a higher relative risk of nonadherence, a history of increased 
adverse asthma outcomes, and may respond differently to interventions due to variable 
health behaviors and beliefs. 30,31 Consequently, we sought to identify patient and family 
level interventions that were effective in improving patient adherence to asthma 
pharmacotherapy in adult African Americans.  
Methods 
Literature Search Strategy 
We searched MEDLINE®, Excerpta Medica dataBASE (EMBASE), Web of Science 
(WOS) and Cumulative Index to Nursing and Allied Health Literature (CINAHL) from 
inception to January-February 2016. An experienced medical librarian conducted the 
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searches and we performed quality checks to ensure that we identified known studies 
on our topic. Our search strategy used a combination of Medical Subject Headings 
(MeSH) terms and key words focused on “asthma”, “adherence” and “African 
American”. See Appendix Tables 1-4 for our full search strategy.  
We searched WOS to identify unpublished studies and conference abstracts.  
We also manually searched the references of pertinent reviews, trials and background 
articles for additional citations that our search may have missed. We determined 
appropriateness of publications by the same inclusion and exclusion criteria as the 
original searches (described below). All citations were imported into an EndNote X7 
electronic database.  
Inclusion and Exclusion Criteria 
The eligibility criteria were developed with the assistance of an expert panel 
(Table 1).  We included studies enrolling adults (age 18 or older) or studies enrolling 
adults and children as long as they reported outcomes separately for adults. We were 
interested in adherence interventions targeting high-risk populations so we limited 
eligibility to adult African American asthmatics.  We excluded studies targeting other 
(non-African American) race/ethnic groups because prior studies have demonstrated 
different barriers to adherence in each race/ethnic group (e.g., cultural beliefs, 
language, immigration status).30,31 We required that studies enroll at least 30% African 
Americans or report subgroup analysis by race. We selected studies with 30% or 
greater African Americans to be inclusive of studies with diverse race/ethnic 
composition but to select for studies that had a larger African American populations 
compared with national percentages.    
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Interventions had to measure asthma pharmacotherapy adherence for at least 
one month and target patients or patient family/care-givers. Follow up was at least one 
month because ICS, first-line therapy for asthma, takes at least four weeks to reach 
maximal efficacy.32-35 We focused on interventions targeting patient and patient-
family/caregivers because we wanted to identify interventions that can empower 
patients and their family/care-givers.  
Our primary outcome of interest was adherence.  We included any measure of 
adherence—objective or subjective. Our secondary outcomes of interest, which did not 
affect eligibility for inclusion, were asthma-related health outcomes, health care 
utilization and intermediate outcomes.  The asthma-related health outcomes included, 
but were not limited to the following: asthma exacerbation, forced expiratory volume in 
one second (FEV1), asthma control, asthma quality of life and mortality.  Health care 
utilization outcomes were defined as any asthma-related or any-cause health services 
use including emergency department, outpatient and hospitalization visits. We limited 
intermediate outcomes to those related to asthma knowledge and self-management.  
Interventions had to be conducted in the United States, or report outcomes 
separately by site if they were multinational studies. We included trials, cohort studies 
and single group pre/post studies published in English.   
Study Selection 
 Two members of the team (IR, ZR, BM) independently reviewed all titles and 
abstracts for eligibility. Full-texts of abstracts or titles that appeared to meet eligibility 
criteria (or could not be fully assessed) were dually reviewed against the same criteria. 
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We reviewed the full text of abstracts or titles marked for inclusion by either reviewer. 
Two team members independently re-reviewed the full text of articles when there was 
an inclusion/exclusion discrepancy; conflicts were resolved by discussion and 
consensus.  
For conference abstracts, we searched for full text articles and additional 
reported outcomes in MEDLINE, google scholar, and the clinicaltrials.gov database.  
We excluded conference abstracts if no associated peer-reviewed publications were 
identified. 
All inclusion and exclusion decisions were tracked in an EndNote database and 
Microsoft Excel®.  We recorded the main reason for exclusion at each stage.   
Data Extraction 
 For studies meeting our inclusion criteria, we designed and used structured data 
extraction forms to gather pertinent information from each article, including study 
participants, design, setting, interventions, comparators, methods, and results.  We 
extracted relevant data and a second member of the research team reviewed it. All data 
abstraction was performed using Microsoft Excel® and Word® software. 
Risk-of-Bias Assessment of Individual Studies 
 We used the AHRQ Methods Guide to assess the risk of bias (internal validity).36 
The criteria included an assessment of selection bias, confounding, performance bias, 
detection bias, and attrition bias.  Appendix Table 5 lists the questions used to assess 
risk of bias.   
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 A study with “low risk of bias” is considered to have valid results and scored 
favorably on most questions with relatively minor unfavorable responses (e.g., lack of 
masking in behavioral interventions).  A study with “moderate risk of bias” was 
concluded to not have major risk of bias but has some risk of bias that will not invalidate 
its results.  However, a study evaluated as “high risk of bias” has errors in design, 
conduct or analysis that may invalidate its results. Common errors in “high risk of bias” 
studies can include high rates of attritions, no intention to treat (ITT) analysis, and use 
of invalid measures of outcomes.   
Two independent reviewers assessed the risk of bias for each study.  We 
resolved disagreement by discussion and consensus.   
Data Analysis and Synthesis 
 To determine whether a meta-analysis was appropriate, we assessed the clinical 
and methodological heterogeneity assessing the PICOTS (population, intervention, 
comparator, outcome, time, setting) of included studies.   
 
Results 
 We identified 1,460 unique titles and abstracts and assessed 171 full texts for 
eligibility (Figure 2). We excluded 168 articles for various reasons (e.g., not conducted 
in the US, exclusive pediatric population, no intervention, not about asthma) and 
included 3 randomized controlled trials (RCTs)37-39 and one single arm pre/post study.40 
Eight of the excluded articles were conference abstracts not published elsewhere. 
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Characteristics of Included Trials 
The 3 RCTs were all head-to-head comparisons of an intensive intervention 
compared with a minimal intervention.37-39 Two RCTs were pilot studies assessing 
feasibility and acceptability.37,39  
Sample sizes ranged from 17 to 333 participants that were predominately middle-
aged African American women.  The percentage of African Americans ranged from 71% 
to 93%; and women made up 69% to 82% of participants. Mean age ranged from 33 to 
47 years. There were no subgroup analyses by age, gender, or race.  All participants in 
the RCTs had persistent asthma and were prescribed an inhaled corticosteroid.37-39 The 
pre/post study targeted hospitalized asthmatics (Table 2).40  
Intervention Characteristics 
Interventions were heterogeneous and focused on problem solving38, self-
efficacy39, the use of patient advocates37, and a pharmacist-led education intervention.40   
The patient advocate intervention included preparing patients for provider visits, 
attending one visit, confirming understanding of issues discussed during the visit, 
facilitating return appointments and following up with patients between visits. College 
educated lay staff members implemented the intervention.37  
The problem solving intervention was a motivational technique to train patients to 
view problems as “inevitable, normal, and solvable”. 38 It consisted of four 30-minute 
sessions tailored to the specific adherence barriers of each patient.  College educated 
lay staff members taught problem solving skills as way to combat medication 
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nonadherence and had subjects apply problem-solving skills to other areas in their lives 
to help solidify real-world application of skills.38    
The self-efficacy intervention coupled clinic-based group sessions with home 
visits to teach asthma self-efficacy skills.39 The intervention included four group 
sessions on asthma management, stress, physical activity and social support and 4 to 6 
community health worker home visits focusing on the patient’s asthma status, asthma 
facts, medications, communication with providers, asthma triggers and cigarette smoke 
avoidance. The group session were implemented by social workers and the home visits 
by community health workers.39  
The pre/post pharmacist intervention consisted of a 30-minute in hospital 
counseling session covering asthma basics, signs and symptoms of exacerbations, 
disease triggers, peak flow monitoring, role of medications and spacers, and adverse 
effects of therapy. Pharmacists reinforced counseling, by phone, at one and five weeks 
after discharge.40   
Two of the four interventions were informed by qualitative analysis.37,39 The self-
efficacy trial used self-efficacy and social learning theory, qualitative analysis and 
cultural adaption to inform intervention development.39 The patient advocate trial used 
qualitative analysis and cultural adaptation to inform the development of their 
intervention.37 However, the pre/post pharmacist intervention and problem solving trial 
did not report using behavior theory, qualitative analysis or cultural adaptation to inform 
the development of their interventions.38,40  
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Comparators for the RCTs focused on asthma education in the form of mailed 
handouts39, a CD37 or four 30-minute in-person sessions about asthma38.  All 
comparator interventions excluded topics of self-management or adherence.    The 
pre/post study did not have comparators.40 
 
Time and Setting 
All interventions were based in an urban health system and recruited from academic 
health centers and clinics serving uninsured and underinsured populations.37-39 Study 
duration ranged from 4 to 6 months.37-40 
 
Outcome Measures 
 All four studies measured adherence.37-39 The patient advocate and problem 
solving trials measured baseline adherence with a validated adherence questionnaire 
specifically designed for ICS and measured 30-day ICS adherence with an electronic 
actuation monitor.37,38 In both trials, two electronic ICS monitors were used because of 
the range in ICS devices (e.g., dry powder inhalers, HFA) used by patients. One device 
could identify dumping of medication by measuring the frequency and time of day of 
actuations and the other could only measure frequency of actuation.  Adherence was 
measured monthly for 4-months in both trials. 37,38    
The self-efficacy trial used a non-validated questionnaire to assess 14-day ICS 
adherence and was measured at baseline, 3 and 6 months.39 The pre/post pharmacist 
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intervention used percent of refills achieved within 10% of targeted refill dates to 
measure monthly and 6 month adherence.40   
 In addition to adherence, included studies measured several other clinical health 
outcomes (e.g., FEV1, asthma control, asthma quality of life), health care utilization 
outcomes (e.g., any ED visit, asthma related ED visit) and intermediate health outcomes 
(e.g. asthma self-efficacy, asthma knowledge). Results are described below.  
Adherence  
All four studies measured adherence defined as 30-day adherence37,38, 14-day 
adherence39, or percent refills achieved within 10% of targeted refill dates40. Among all 
three RCTS, none reported a statistically significantly difference between the 
intervention and comparator groups.37-39 For the pre/post pharmacist intervention, 
measuring timely refills, they reported a statistically significant increased mean 
adherence rate (SD) of 22% (6) to 63% (24) over 6 months, p=0.0175.40 
  
Asthma Health Outcomes 
 All three RCTs measured asthma control37-39, FEV137,38, and asthma quality of 
life (AQLQ) 37-39.  Most outcomes were not statistically significant.  However, the self-
efficacy trial found a statistically significant improvement in asthma quality of life 
(AQLQ), measured by mini-AQLQ, in the intervention arm versus the comparator arm 
(adjusted difference between groups: 1.8, p=0.002). The difference was clinically 
significant (greater than 0.5) and adjusted for baseline characteristics and propensity 
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scores.39 The pre/post pharmacist intervention did not measure asthma health 
outcomes.40 
 
Health Care Utilization Outcomes 
 The patient advocate, problem solving and pre/post pharmacist interventions 
measured health care utilization outcomes.37,38,40 The pre/post pharmacist study 
reported a statistically significantly lower rate of asthma-related ED or hospital visits 
after patients received the intervention, mean visits (SD) 1.58 (1.13) to 0.35 (0.62), 
p=0.0016. 40   
The patient advocate and problem solving trials did not find a statistically 
significant difference in asthma-related or any-cause emergency department visits or 
hospitalizations between patients in the intervention and comparator arms.37,38  
 
Intermediate Outcomes 
 The self-efficacy trial was the only trial to measure intermediate outcomes (i.e., 
asthma knowledge and self-efficacy) other than adherence.39 The authors developed 
and validated a self-efficacy measure adapted from existing self-efficacy scales. They 
reported a transient increase in self-efficacy with a 3-month adjusted difference 0.8 (p 
<0.001; 95% CI, 0.4-1.3), but had a non-significant difference at 6 months.  There was 
no change in asthma knowledge.39 
 
Study Quality 
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We rated all three RCTs as medium risk of bias37-39 and the pre/post study as 
high risk of bias.40 The pre/post study received high risk of bias due to its susceptibility 
to selection bias and moderate detection bias due to the use of self-reported outcome 
measures. 
The patient advocate and problem solving trials were rated as medium risk of 
bias due to attrition and measurement bias but both trials adequately adjusted for 
missing data using linear mixed effects modeling.37,38 In the patient advocate trial, 272 
(68%) adherence outcomes were recorded. Of the 128 that were missing, 48 (37%) were due to 
equipment failure, 50 (39%) due to monitor not returned and for 30 (23%) due to the patient 
never bringing in a medication to attach the monitor. There was no difference in distribution of 
missing adherence data by treatment group.37 
The problem solving trial had similar issues.  Adherence monitor downloads failed in 380 
(20%) of 2360 downloads, 18% of the intervention group and 22% of the control.38 Failures were 
again attributed to monitor failure, battery failure, and proximity to other batteries or magnets 
(Table 3).38  
 
Discussion 
Among over 1460 studies screened, we identified four studies in the literature 
examining patient and family-level pharmacotherapy adherence interventions for adult 
AA.  Three had small sample sizes,37,39,40 three were RCTs37-39 and one had high risk of 
bias due to study design.40 Among the interventions, only the pre/post pharmacist-led 
intervention was effective in improving adherence and reducing health care utilization; 
however, it targeted hospitalized asthmatics and at least half were not on ICS on 
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admission.40 The other trials targeted persistent asthmatics that were prescribed ICS. 
These trials showed no improvement in adherence, asthma control, FEV1, or asthma 
knowledge.37-39 One of these studies, designed to improve asthma self-efficacy, 
reported improved asthma quality of life but no long-term change in asthma self-
efficacy.39   
 The lack of effectiveness of interventions could be due to several factors.  First, 
the active controls could have mitigated the effect size.  The problem solving study 
noted an overall improvement in asthma control, AQLQ, and FEV1. The authors 
ascribed the improvement in clinical outcomes to 66% of the control group thinking that 
the goal of the basic asthma education program (control arm) was to educate 
individuals on the importance of medication adherence.38 Second, the Hawthorne effect 
could have affected outcomes.  Monitoring adherence with an electronic counter is not a 
benign intervention and can stimulate adherence in the control arm and reduce effect 
size.37,38,41 Third, only the problem solving study was powered to detect a change in 
adherence.38 The patient advocate and self-efficacy trials were feasibility and 
acceptability trials that were not powered to see changes in clinical outcomes.37,39 
 Our results are consistent with findings in other systematic reviews.  Press et al., 
found a paucity of interventions targeting adult AA asthmatic interventions and few 
rigorous study designs.42 A 2014 Cochrane review also confirmed that there were few 
RCTs that improved adherence and clinical outcomes. 29 However an AHRQ systematic 
review found that policy interventions were most effective at improving adherence 
across conditions and included interventions to reduce copayments, improve 
prescription coverage, case management interventions, and patient-level education 
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interventions with behavioral support.25   
Future studies are needed focusing on quality adherence clinical trials in high-
risk populations such as adult AA.  We recommend increasing the measure of 
adherence as a secondary outcome in clinical trials to supplement the observational 
literature, the use of objective measures of adherence, the integration of education, 
behavioral and policy approaches to improve adherence and clinical outcomes, and the 
use of behavior theory and qualitative methods to inform study design. Lastly, there 
needs to be an exploration of the unique barriers and facilitators to high-risk 
populations’ response to standard adherence interventions.  
There are a few limitations of our review.  First publication bias may limit our 
findings.  However, we reviewed conference abstracts to minimize publication bias.  
Second, we were not able to perform a meta-analysis due to the heterogeneity of 
interventions. Third, we limited to studies with “African American” search terms and at 
least 30% AA.  Using the “African American” search term could have excluded studies 
that did not focus on asthma disparities or high-risk populations.  However, we 
supplemented the database searches and conference abstracts with a review of prior 
medication adherence systematic reviews and minority asthma intervention systematic 
reviews.  Limiting to 30% could have excluded studies but a prior systematic review of 
asthma interventions in minorities used 50% as a limit.  We used 30% as conservative 
limit between the national percentage of AA (13.2%) and the limit used in a prior review 
(50%).42  
In conclusion, few studies assessing asthma adherence interventions focused on 
adult AA populations. Data from one RCT suggests that interventions focused on self-
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efficacy improve asthma related quality of life compared with controls. Although one 
pre/post study found improved adherence with a pharmacist-led intervention, none of 
the 3 included RCTs demonstrated improved adherence in participants randomized to 
an active intervention compared with controls. Future studies are needed which use 
rigorous study design, are informed by theory and qualitative data, and integrate 
education, behavioral and policy approaches to improve adherence and clinical 
outcomes and reduce health disparities. 
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Figure 1: Analytic framework for interventions to improve adherence to asthma 
pharmacotherapy in adult African American asthmatics 
 
Key Question: What patient and family level interventions are effective in improving patient 
adherence to asthma pharmacotherapy in adult Black/African Americans? 
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Table 1: Inclusion and Exclusion Criteria 
 Inclusion Exclusion 
P
- p
op
ul
at
io
n 
1. Asthmatics (at least 80% of study 
population are asthmatics) 
2. Age 18 years or older 
3. Mixed adult and pediatric populations 
when authors report outcomes separately 
for pediatric and adult groups or if at least 
80% are adults 
4. At least 30% Black/African American 
study population  
5. Less than 30% Black/African American 
when subgroup analysis is performed 
 
 
All other populations 
I- 
in
te
rv
en
tio
n 
1. Asthma pharmacotherapy adherence 
promotion intervention 
- Example: medication reminder system, 
multi-component intervention that 
measures asthma pharmacotherapy 
adherence 
2. Family and/or patient level intervention  
1. Interventions solely targeting 
providers, health systems, or any 
non-patient/family entity.  
- Example: EHR reminders for 
providers  
2. Interventions not measuring 
asthma pharmacotherapy 
adherence 
C
- c
om
pa
ra
to
r 1. Active or usual care comparator None 
O
- o
ut
co
m
es
 
Primary Outcome: Any measure of 
adherence including objective or self-
reported 
- no pre-specified definition 
 
Secondary Outcomes:  
1. Health outcomes- any measures of 
asthma morbidity and mortality 
- Not limited to asthma exacerbation, 
asthma control, asthma quality of Life, 
mortality 
2. Health utilization outcomes- any use of 
health care services including emergency 
department, outpatient and hospitalization 
visits. 
3. Intermediate outcomes- asthma 
knowledge and self-management 
Intermediate outcomes not listed 
in inclusion criteria 
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T-
 p
re
vi
ou
s 
tim
e 
ov
er
 w
hi
ch
 to
 
re
vi
ew
 li
te
ra
tu
re
 Databases (from inception):  
1. MEDLINE  
2. CINAHL 
3. EMBASE 
4. Web of Science 
 
T-
 ti
m
e 
al
lo
tte
d 
fo
r 
ou
tc
om
es
 to
 
ap
pe
ar
 
At least 1 month  Less tan 1 month 
S
- s
tu
dy
 
de
si
gn
s 
al
lo
w
ed
 1. Trials (randomized and non-randomized) 
2. Cohort studies with a concurrent control 
3. Single group pre/post 
1. Case series 
2. Case control 
3. Systematic reviews 
4. Conference abstracts  
S
- s
et
tin
g 
al
lo
w
ed
 1. Conducted in the US 
2. Multi-country study if data reported by 
country 
No study site in the US 
P
ub
lic
at
io
n 
La
ng
ua
ge
 English 
 
All other languages 
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Figure 2: Article Review Flow Diagram 
 
 
EMBASE- Excerpta Medica dataBASE, WOS- Web of Science, CINAHL-Cumulative 
Index to Nursing and Allied Health Literature 
*Other: 1 full text unavailable, 2 duplicates, 4 full text included in search results, 8 
conference abstracts with insufficient information 
